Avacincaptad pegol
- Generic Name
- Avacincaptad pegol
- Brand Names
- Izervay
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1613641-69-2
- Unique Ingredient Identifier
- TT0V5JLG5B
- Background
Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule. It was developed to treat an advanced form of age-related macular degeneration (AMD) called geographic atrophy (GA). AMD is the leading cause of vision loss in developed countries for people over 50 years old, with a global estimate of 170 million individu...
- Indication
Avacincaptad pegol is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Associated Conditions
- Dry Macular Degeneration
- Associated Therapies
- -
Astellas Pharma Withdraws EU Application for Key Drug
Astellas Pharma withdrew its marketing application for avacincaptad pegol from the EMA due to interactions, despite positive U.S. results. The company remains optimistic about the drug's benefits and committed to global regulatory engagement.
VIDEO: US specialist sympathizes with EU colleagues over EMA rejection of pegcetacoplan
US specialist Baruch D. Kuppermann sympathizes with EU colleagues over EMA's rejection of pegcetacoplan, noting the disappointment in limited treatment options for geographic atrophy patients.
Enrollment complete of phase 2b of SIGLEC study to assess safety and efficacy of AVD-104
Aviceda Therapeutics has completed enrollment for the phase 2b SIGLEC Study, assessing AVD-104's safety and efficacy in treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study compares high- and low-dose AVD-104 with avacincaptad pegol, with 100 patients enrolled in each arm. AVD-104, an optimized intravitreal glycomimetic nanoparticle, aims to inhibit macrophage and complement cascade amplification. The 12-month data is expected in the second half of 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath